Get the Stockscreener App
9.09
5.09%
0.44
After Hours:
9.03
-0.06
-0.66%
Xilio Therapeutics Inc stock is traded at $9.09, with a volume of 37,611.
It is up +5.09% in the last 24 hours and up +0.44% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
See More
Previous Close:
$8.65
Open:
$8.65
24h Volume:
37,611
Relative Volume:
0.77
Market Cap:
$59.77M
Revenue:
$43.77M
Net Income/Loss:
$-35.04M
P/E Ratio:
-2.7951
EPS:
-3.2521
Net Cash Flow:
$-5.51M
1W Performance:
+6.07%
1M Performance:
+0.44%
6M Performance:
+5.57%
1Y Performance:
-6.81%
1-Day Range:
$8.44
$9.1899
1-Week Range:
$8.31
$9.1899
52-Week Range:
$6.4652
$12.74
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
9.09 | 56.87M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
XLO|Xilio Therapeutics Inc|Price:8.930|Chg%:+0.280 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
XLO|Xilio Therapeutics Inc|Price:8.650|Chg%:+0.340 - TradingKey
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics (XLO) Holds Near Support After Modest DeclineRTH Profile - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady Near Resistance – Biotech Stock in Tight RangeInsider Selling Alerts - dars.gov.et
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics (XLO) Slides 2% as Biotech Stock Tests Key Support LevelsVolume Rate Change - dars.gov.et
Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics (XLO) Slides as Biotech Sector Headwinds PersistVolume Profile - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - Investing.com
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pipeline ProgressEPS Estimate Trend - dars.gov.et
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell 3000E Value Benchmark - marketscreener.com
XLO Forecast — Price Target — Prediction for 2027 - TradingView
Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO) - TradingView
Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XLO Price Today: Xilio Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Xilio Therapeutics Inc (XLO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Institutional Confidence - TradingKey
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes - The Globe and Mail
Daniel Curran reappointed to Class III director at Xilio - TradingView
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Xilio (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options - Stock Titan
Xilio Therapeutics (XLO) director receives 5,000 stock options at $7.99 strike - Stock Titan
Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99 - Stock Titan
Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO) - Stock Titan
Top Lunai Bioworks (LNAI) Competitors 2026 - MarketBeat
Xilio Therapeutics (XLO) Edges Higher, Testing Resistance After Modest GainsVolume Gap - dars.gov.et
XLO Q1 2026 Earnings: Narrower Loss Surprises, Clinical Progress ContinuesTangible Book Value - dars.gov.et
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):